Literature DB >> 2803975

Circulating erythropoietin in patients with myelodysplastic syndromes.

A Jacobs1, A Janowska-Wieczorek, J Caro, D T Bowen, T Lewis.   

Abstract

Serum concentration of erythropoietin (Epo) has been measured by radioimmunoassay in 46 patients with myelodysplastic syndromes. There is an overall inverse relationship between the level of Epo and the degree of anaemia but a wide range of Epo response between patients with similar haemoglobin concentrations. No differences were found between the different FAB groups, but the highest Epo levels were found in those patients with erythroid hypoplasia in the bone marrow. It is suggested that the intensity of erythroid activity in the marrow, as well as the degree of anaemia, may be a factor determining serum Epo concentration.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2803975     DOI： 10.1111/j.1365-2141.1989.tb00215.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  9 in total

1.  Serum erythropoietin level: relationships to blood hemoglobin concentration and erythrocytic activity of the bone marrow.

Authors:  W Jelkmann; G Wiedemann
Journal:  Klin Wochenschr       Date:  1990-04-17

2.  NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Authors:  Peter L Greenberg; Eyal Attar; John M Bennett; Clara D Bloomfield; Carlos M De Castro; H Joachim Deeg; James M Foran; Karin Gaensler; Guillermo Garcia-Manero; Steven D Gore; David Head; Rami Komrokji; Lori J Maness; Michael Millenson; Stephen D Nimer; Margaret R O'Donnell; Mark A Schroeder; Paul J Shami; Richard M Stone; James E Thompson; Peter Westervelt
Journal:  J Natl Compr Canc Netw       Date:  2011-01       Impact factor: 11.908

Review 3.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

4.  Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.

Authors:  Y Yoshida; N Anzai; H Kawabata; Y Kohsaka; M Okuma
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

Review 5.  Erythropoietin: a review.

Authors:  D M Ridley; F Dawkins; E Perlin
Journal:  J Natl Med Assoc       Date:  1994-02       Impact factor: 1.798

Review 6.  Hematopoietic growth factors and the treatment of tumor-associated anemias.

Authors:  U Dührsen; D K Hossfeld
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

7.  Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.

Authors:  G E Verhoef; P Zachée; A Ferrant; H Demuynck; D Selleslag; L Van Hove; F Deckers; M A Boogaerts
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

8.  Myelodysplastic syndromes: clinical practice guidelines in oncology.

Authors:  Peter L Greenberg; Eyal Attar; John M Bennett; Clara D Bloomfield; Uma Borate; Carlos M De Castro; H Joachim Deeg; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Steven D Gore; David Head; Rami Komrokji; Lori J Maness; Michael Millenson; Margaret R O'Donnell; Paul J Shami; Brady L Stein; Richard M Stone; James E Thompson; Peter Westervelt; Benton Wheeler; Dorothy A Shead; Maoko Naganuma
Journal:  J Natl Compr Canc Netw       Date:  2013-07       Impact factor: 11.908

9.  Autonomous proliferation and bcl-2 expression involving haematopoietic cells in patients with myelodysplastic syndrome.

Authors:  C Bincoletto; S T Saad; E Soares da Silva; M L Queiroz
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.